

ESKETAMINE nasal spray solution (Spravato® ▼) for treatment-resistant depression

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ESKETAMINE nasal spray solution (Spravato® ▼) for treatment-resistant depression.

GREY

Esketamine, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.¹

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of treatment-resistant depression should continue to follow national guidance, local pathways and local formulary choices.

- > NICE CG90 [Depression in adults: recognition and management](#) (October 2009)
- > NICE Pathway [Depression](#) (last updated: 11 February 2020)
- > Pan Mersey APC Formulary [Antidepressant drugs](#)

References

1. Janssen-Cilag Ltd. Summary of Product Characteristics; [Spravato 28 mg nasal spray, solution](#), 18 December 2019. Accessed online 17 February 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.